OncoMatch/Clinical Trials/NCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Is NCT07038343 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AVZO-1418 and Combination Agent 1 for solid tumor cancer.
Treatment: AVZO-1418 · Combination Agent 1 · Combination Agent 2 — This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Avenzo Therapeutics Recruiting Site · Gilbert, Arizona
- Avenzo Therapeutics Recruiting Site · Los Angeles, California
- Avenzo Therapeutics Recruiting Site · Denver, Colorado
- Avenzo Therapeutics Recruiting Site · New Haven, Connecticut
- Avenzo Therapeutics Recruiting Site · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify